Dr. Johan Lundin, Research Director, MD, PhDfor the Institute for Molecular Medicine Finland (FIMM) and Nordic EMBL Partnership for Molecular Medicine, discovered a way to get everyone on the same page or in this case, look at the same areas of a sample simultaneously with one microscope.
"We are thrilled to be able to offer the only FDA-approved long-term therapy for people suffering from advanced RP, " said Robert Greenberg, MD, PhD, President and CEO of Second Sight.